Mendelspod Podcast

Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine. www.mendelspod.com

Mendelspod Podcast is a science podcast hosted by Theral Timpson, with 561 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Theral Timpson hosts Mendelspod Podcast, a science show with 561 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Mendelspod Podcast

  Ryan Flynn of Harvard on Non-Coding RNA

  Jun 18, 202641 minS0

  <p>On today’s show, Dr. Ryan Flynn of Harvard Medical School and Boston Children’s Hospital takes us into a newly emerging layer of biology: the architecture of the cell surface itself. Flynn first gained attention for the discovery of glycoRNA — RNA molecules displayed on the outside of cells — a finding that challenged the traditional picture of the cell surface as a world composed primarily of proteins and glycans. RNA has long been understood mainly as a carrier of genetic information (messenger RNA), but Flynn’s work has show that it has other functions critical to basic processes in the cell...

  ListenShow Notes
• 

  Mendelspod Podcast

  Gary Schroth on Connecting Cellular Behavior to the Transcriptome

  Jun 11, 202633 minS0

  <p>For decades, biology has been driven by the powerful notion that if we could sequence enough genomes, transcriptomes, epigenomes, then we could finally explain the cell. On today’s show, Gary Schroth, the Chief Scientific Officer at Cellanome, argues that something essential was still missing.</p><p>Schroth spent nearly two decades at Illumina helping build the sequencing revolution. He has now joined Cellanome to pursue an expanded vision of biology that connects transcriptomics with live-cell imaging. Our conversation centers around two newly released preprints describing the company’s platform and its application to CRISPR screening, where imaging and tran...

  ListenShow Notes
• 

  Mendelspod Podcast

  Two-Thirds of High-Risk Breast Cancer Patients May Avoid Chemotherapy According to Veracyte Data Presented at ASCO

  Jun 9, 202627 minS0

  <p>Today on the show, we’re discussing a new study just presented at ASCO 2026 that could change how chemotherapy decisions are made for a large group of breast cancer patients.</p><p>During ASCO we spoke with Phil Febbo, Chief Scientific and Medical Officer at Veracyte, and John Leite, the company’s Chief Commercial Officer, looking at the results from the OPTIMA study, a large prospective trial involving roughly 4,500 patients with clinically high-risk ER-positive, HER2-negative breast cancer. The study found that about two-thirds of these patients could safely avoid chemotherapy when treatment decisions were guided by the Prosigna test...

  ListenShow Notes
• 

  Mendelspod Podcast

  Building the Diagnostic Layer of Modern Cancer Care with Rita Shaknovich and Karina Kulangara of Agilent

  May 29, 202632 minS0

  <p>For years, precision oncology has largely been discussed through the lens of breakthrough drugs. But there’s another story running underneath modern cancer care: the quiet rise of companion diagnostics. These tests are increasingly deciding who receives those therapies in the first place. In many cases, the real bottleneck is no longer discovering a drug target. It’s building a reliable system for identifying the right patient at the right moment in the disease. That challenge sits at the center of this conversation with Rita Shaknovich, Chief Medical Officer for Life Sciences and Diagnostis, and Karina Kulangara, Associate Vice Pres...

  ListenShow Notes
• 

  Mendelspod Podcast

  Mapping the Multi-Omic Era with Eric Green of Illumina

  May 28, 202644 minS0

  <p>Dr. Eric Green returns to Mendelspod in a new role: Chief Medical Officer of Illumina. After more than three decades at the National Human Genome Research Institute, where he helped guide genomics from research initiatives to clinical reality, he now joins one of the industry’s most influential companies at a moment when the field is expanding beyond DNA alone.</p><p>Green takes us on a tour around the world of multi-omics, which he says is not a branding exercise but a practical response to the limits of sequence data by itself. Genomics remains foundational, but many clinical qu...

  ListenShow Notes

Recent guests on Mendelspod Podcast. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.